Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy

NCT07256002 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

10000

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer (NSCLC)

Interventions

DRUG: PD-1 Inhibitors
DRUG: Chemotherapy
DRUG: PD-1 inhibitors combined with chemotherapy

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences